MedTrace Logo

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05190068 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2025-04-09

No results posted yet for this study

Summary

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Conditions

  • B-Cell Non-Hodgkin's Lymphoma

Interventions

DRUG

HMPL-760

HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Weili Zhao, Ph.D · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2025-01-27
Completion
2025-01-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190068 on ClinicalTrials.gov